Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Recruiting 9Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

Azacitidine 15Cyclophosphamide 13fludarabine phosphate 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8venetoclax 7Tacrolimus 7Cyclosporine 7Busulfan 7Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5Decitabine 5Cord Blood Stem Cell Transplantation 5Rituximab 4Arsenic Trioxide 4Sunitinib 3Sorafenib 3Methylprednisolone 3Melphalan 3Leucovorin 3Clofarabine 3ruxolitinib 2ponatinib 2idelalisib 2Sirolimus 2Moxifloxacin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelomonocytic, Chronic × fludarabine × Clear all
NCT01773395 2022-07-18

GVAX vs. Placebo for MDS/AML After Allo HSCT

Dana-Farber Cancer Institute

Phase 2 Terminated
123 enrolled 26 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡